Tumor endothelial cells join the resistance.
The field of antiangiogenesis research has been met with some surprises, including the realization that tumor blood vessels are more complex and labile than expected. In this issue of Clinical Cancer Research, Xiong and colleagues show that tumor-specific endothelial cells are less sensitive to cytotoxic and antiangiogenic drugs compared to their normal counterparts.
Dudley
Andrew C
AC
Vascular Biology Program, Departments of Surgery and Pathology, Harvard Medical School, Boston, MA 02115, USA. andrew.dudley@childrens.harvard.edu
Klagsbrun
Michael
M
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates / Q000494:pharmacology; D000068258:Bevacizumab; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000473:pathology*; D002478:Cells, Cultured; D019008:Drug Resistance, Neoplasm; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000473:pathology*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000494:pharmacology; D000069579:Ranibizumab; D000077157:Sorafenib
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D000069579:Ranibizumab